SCHEMBL4501318

SCHEMBL4501318

CCN1C(=O)C(C)(C)c2ccc(N)cc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATAD2 Q6PL18 1/20 0.44
AURKA O14965 2/20 0.40
AURKB Q96GD4 2/20 0.40
CYP19A1 P11511 1/20 0.38
ALDH1A1 P00352 4/20 0.38
KDM4E B2RXH2 3/20 0.38
MAPT P10636 3/20 0.38
GAA P10253 2/20 0.38
GFER P55789 1/20 0.38
MARK3 P27448 1/20 0.36
CHEK1 O14757 2/20 0.36
SRC P12931 1/20 0.36
CDK2 P24941 1/20 0.36
KDR P35968 1/20 0.36
FLT3 P36888 1/20 0.36
GSK3B P49841 1/20 0.36
OPRM1 P35372 1/20 0.36
OPRL1 P41146 1/20 0.36
CNR1 P21554 1/20 0.35
GPR55 Q9Y2T6 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1368159 0.87 ATAD2 (0.48) ATAD2AURKAAURKBCYP19A1ALDH1A1
SCHEMBL14401726 0.81 BACE1 (0.38) ATAD2ALDH1A1GAABACE1TDP1
SCHEMBL18719875 0.81 AURKA (0.40) AURKAAURKBALDH1A1KDM4EMAPT
SCHEMBL17275707 0.81 ALDH1A1 (0.47) AURKAAURKBALDH1A1MAPTMARK3
SCHEMBL2486094 0.80 AURKA (0.44) ATAD2AURKAAURKBCYP19A1ALDH1A1
Hydrochloric Acid SCHEMBL10696532 0.79 AURKA (0.43) ATAD2AURKAAURKBCYP19A1ALDH1A1
SCHEMBL26621462 0.79 TP53 (0.32) ATAD2MAPTMEN1KMT2ATDP1
SCHEMBL31702288 0.79 ALDH1A1 (0.43) ALDH1A1MAPTGAAOPRL1MEN1
SCHEMBL2144650 0.78 MEN1 (0.40) AURKAAURKBCYP19A1CHEK1KDR
SCHEMBL31251176 0.78 MEN1 (0.40) AURKAAURKBCYP19A1CHEK1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104619701-B For treating 2-oxo-2 of CNS disease, 3-Dihydro-indole compounds 霍夫曼-拉罗奇有限公司 2016-10-19 CN disclosed
EP-2895476-B1 2-OXO-2,3-DIHYDRO-INDOLES FOR THE TREATMENT OF CNS DISORDERS HOFFMANN LA ROCHE (CH) 2016-06-22 EP disclosed
US-9221816-B2 2-oxo-2,3-dihydro-indoles for the treatment of CNS disorders HOFFMANN LA-ROCHE INC. (US) 2015-12-29 US disclosed
US-20150284386-A1 2-OXO-2,3-DIHYDRO-INDOLES FOR THE TREATMENT OF CNS DISORDERS HOFFMANN-LA ROCHE INC. (US) 2015-10-08 US disclosed
EP-2895476-A1 2-OXO-2,3-DIHYDRO-INDOLES FOR THE TREATMENT OF CNS DISORDERS F. Hoffmann-La Roche AG (CH) 2015-07-22 EP disclosed
CN-104619701-A 2-oxo-2,3-dihydro-indoles for the treatment of cns disorders HOFFMANN LA ROCHE 2015-05-13 CN disclosed
WO-2014040969-A1 2-OXO-2,3-DIHYDRO-INDOLES FOR THE TREATMENT OF CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2014-03-20 WO disclosed
US-20090291968-A1 SUBSTITUTED INDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS GEORGES GUY 2009-11-26 US disclosed
CN-101400681-A Substituted indazole derivatives, their manufacture and use as pharmaceutical agents HOFFMANN LA ROCHE (CH) 2009-04-01 CN disclosed
US-7462639-B2 e.g 3-(7,7-Dimethyl-6-oxo-1,5,6,7-tetrahydro-imidazo[4,5-f]indol-2-yl)-1H-pyrazol-4-yl]-carbamic acid benzyl ester; Aurora A (serotonin/threonine) kinase inhibitors; anticarcinogenic agent; colorectal, breast, lung, prostate, pancreatic, gastric, bladder, ovarian cancer, melanoma, neuroblastoma HOFFMANN-LA ROCHE INC. (US) 2008-12-09 US disclosed
CN-101160312-A Tricyclic azole derivatives, their preparation and use as pharmaceutical agents HOFFMANN LA ROCHE (CH) 2008-04-09 CN disclosed
CN-101160313-A Aminopyrazole derivatives, their preparation and use as pharmaceutical agents HOFFMANN LA ROCHE (CH) 2008-04-09 CN disclosed
CN-101080408-A Trycyclic heterocycles, their manufacture and use as pharmaceutical agents HOFFMANN LA ROCHE (CH) 2007-11-28 CN disclosed
WO-2007120339-A1 PYRIMIDINE KINASE INHIBITORS GENENTECH, INC. (US) 2007-10-25 WO disclosed
US-7285569-B2 Tricycles, their manufacture and use as pharmaceutical agents HOFF HOFFMANN-LA ROCHE INC. (US) 2007-10-23 US disclosed
CN-101027055-A Tricycles, their manufacture and use as pharmaceutical agents HOFFMANN LA ROCHE (CH) 2007-08-29 CN disclosed
US-20060235065-A1 Aminopyrazole derivatives HOFFMANN-LA ROCHE INC. 2006-10-19 US disclosed
US-20060235013-A1 Tricyclic azole derivatives F. HOFFMANN-LA ROCHE AG (CH) 2006-10-19 US disclosed
US-20060142247-A1 Tricyclic heterocycles HOFFMANN-LA ROCHE INC. 2006-06-29 US disclosed
US-20060069145-A1 Tricycles, their manufacture and use as pharmaceutical agents F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2006-03-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291968-A1 SUBSTITUTED INDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS CYP3A43, CYP3A5, CYP3A7 ATAD2 4097/4885AURKA 1558/4885AURKB 2087/4885
US-20060235013-A1 Tricyclic azole derivatives CYP3A5, CYP3A43, CYP11B1 ATAD2 4258/4885AURKA 1207/4885AURKB 1249/4885
US-20060235065-A1 Aminopyrazole derivatives CYP3A43, CYP3A5, CYP3A4 ATAD2 1904/4885AURKA 742/4885AURKB 1096/4885
US-20060069145-A1 Tricycles, their manufacture and use as pharmaceutical agents ABCB1, CYP3A43, CYP3A5 ATAD2 4632/4885AURKA 1724/4885AURKB 1606/4885
US-20060142247-A1 Tricyclic heterocycles CYP11B1, CYP11B2, CYP3A43 ATAD2 4449/4885AURKA 2529/4885AURKB 2155/4885
US-20150284386-A1 2-OXO-2,3-DIHYDRO-INDOLES FOR THE TREATMENT OF CNS DISORDERS HCRTR2, TPH2, CNR2 ATAD2 3556/4885AURKA 2861/4885AURKB 2412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.